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PURPOSE.We hypothesized that longitudinal changes in corneal nerve morphology would
differ between the central cornea and inferior whorl in relation to other measures of
diabetic neuropathy.
METHODS. Thirty patients with diabetes (age: 54.08 ± 15.86, duration: 23.95 ± 14.2,
HbA1c: 7.51 ± 1.37) and 19 age-matched healthy controls (age: 49.47 ± 13.25) underwent
assessment of neuropathy disability score (NDS), vibration perception threshold (VPT),
cold (CPT) and warm (WPT) perception thresholds, peroneal motor nerve conduction
velocity (PMNCV), corneal nerve fiber density (CNFD), branch density (CNBD), fiber
length (CNFL), inferior whorl length (IWL), and the average of CNFL and IWL (ANFL) at
baseline and after 1 to 8 years.
RESULTS. In patients with diabetes, between baseline and follow-up, there was a signif-
icant reduction in CNBD (57.72 ± 30.08 vs. 44.04 ± 23.69; P = 0.02), CNFL (21.77 ±
5.19 vs. 15.65 ± 4.7; P < 0.0001), IWL (24.69 ± 8.67 vs. 14.23 ± 6.13; P < 0.0001), ANFL
(23.26 ± 5.53 vs. 15.09 ± 4.48; P < 0.0001), and WPT (43.56 ± 4.43 vs. 40.78 ± 4.93;
P = 0.01), and an increase in VPT (12.9 ± 8.96 vs. 13.78 ± 8.99; P = 0.02). There was no
significant change in CNFD (27.12 ± 8.2 vs. 25.43 ± 7.11; P = 0.2), NDS (3.38 ± 3.35 vs.
2.61 ± 2.8; P = 0.08), CPT (17.7 ± 10.59 vs. 22.45 ± 9.23; P = 0.06), or PMNCV
(42.4 ± 4.21 vs. 42.16 ± 6.3; P = 0.2).
CONCLUSIONS. There is evidence of corneal nerve loss in patients with diabetes, particularly
at the inferior whorl during follow-up.
Keywords: corneal nerves, diabetes mellitus, corneal confocal microscopy
Corneal confocal microscopy (CCM) is a rapid noninva-sive ophthalmic imaging technique to quantify corneal
nerve morphology,1 and corneal nerve loss is related to the
severity of diabetic neuropathy.2,3 We have recently demon-
strated good diagnostic ability of CCM in a large cohort of
patients with diabetic neuropathy.4 The corneal sub-basal
nerve plexus is comprised of unmyelinated nerve fibers,
which course from the peripheral cornea to the central
cornea, and then radiate to the more distal inferior whorl
(IW).5,6 Most studies have shown a loss of corneal nerves
in the central cornea.3,7,8 However, more recent studies
in experimental animals9 and patients with diabetes10–13
have shown a reduction in corneal nerves at the IW in
patients without diabetic peripheral neuropathy (DPN) and
an association with the severity of painful diabetic neuropa-
thy and poorer quality of life.11 Furthermore, the IW is an
anatomically distinct structure, which allows more accurate
assessment of longitudinal changes in the sub-basal nerve
plexus.12
Previously, very few studies have assessed change
in corneal nerve morphology longitudinally.8,14–16 In the
current study, we have compared longitudinal changes in
corneal nerve morphology in the central cornea and at the
IW in relation to other measures of neuropathy.
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METHODOLOGY
Study Subjects
Thirty patients with type 1 (n= 21) or type 2 (n= 9) diabetes
and 19 age- and sex-matched healthy participants under-
went detailed assessment of peripheral neuropathy and CCM
at baseline and follow-up while receiving standard of care
for diabetes management.We hypothesized that longitudinal
changes in corneal nerve morphology would differ between
the central cornea and IW in relation to other measures of
diabetic neuropathy.
The follow-up visit for each participant ranged between
1 and 8 years, with an average 3.6 ± 1.3 years for patients
with diabetes and 5.0 ± 1.75 years for controls. Patients
with a history of or any other cause of neuropathy (malig-
nancy, deficiency of B12 or folate, chronic renal, liver
failure, connective tissue or systemic disease), current or
active diabetic foot ulceration, previous corneal trauma or
systemic disease that affects the cornea, surgery and a
history of or current contact lens wear were excluded from
the study. Each participant provided informed consent, and
the research adhered to the tenets of the Declaration of
Helsinki and was approved by Greater Manchester East
Research Ethics Committee.
Clinical and Peripheral Neuropathy Assessment
Body mass index (BMI), blood pressure (BP), (glycated
hemoglobin) HbA1c, and lipid profile were assessed in
each participant. Neuropathy disability score (NDS) was
used to quantify vibration, pinprick, temperature percep-
tion, and presence or absence of ankle reflexes.17 Vibration
perception threshold (VPT) was evaluated using a Neuroth-
esiometer (Scientific Laboratory Supplies, Wilford, Notting-
ham, UK), and cold perception threshold (CPT) and warm
perception threshold (WPT) were tested on the dorsolat-
eral aspect of the nondominant foot (S1) using a TSA-II
NeuroSensory Analyser (Medoc, Ltd., Ramat-Yishai, Israel).
Electrodiagnostic studies were undertaken by a consultant
neurophysiologist using a Dantec “Keypoint” system (Dantec
Dynamics Ltd., Bristol, UK) equipped with DISA tempera-
ture regulator to keep the limb temperature at 32°C to 35°C,
and peroneal motor nerve conduction velocity (PMNCV) was
tested.
Ophthalmic Assessment
Examinations of the anterior ocular segment using slit-
lamp biomicroscopy, and CCM examination using laser
scanning CCM HRT III (Heidelberg Retinal Tomograph III
Rostock Cornea Module; Heidelberg Engineering, Heidel-
berg, Germany) were performed for both eyes according to
our established protocol.10,18
Corneal Nerves
We selected six images (three per eye) from the central
sub-basal nerve plexus and four images from the IW
region and manually quantified corneal nerve morphology
using CCMetrics (University of Manchester, Manchester, UK).
Images were selected by a single expert in a masked fashion
taking into account the quality, depth, and variability using
an established protocol.10,19 We quantified five corneal nerve
parameters: corneal nerve fiber density (CNFD: total number
of main nerves per square millimeter) (no./mm2), corneal
nerve branch density (CNBD: total number of branches per
square millimeter) (mm/mm2), corneal nerve fiber length
(CNFL: total length of main nerves and nerve branches per
square millimeter) (mm/mm2), inferior whorl length (IWL:
total length of nerves per square millimeter) (mm/mm2),
and average nerve fiber length (ANFL = CNFL + IWL/2)
(mm/mm2).
Statistical Analyses
The analysis was carried out using SPSS Version 22.0
for Macintosh (IBM Corporation, Armonk, NY, USA). The
Shapiro-Wilk test was employed to assess whether the data
were normally distributed. Paired and independent t-tests
(Wilcoxon matched-pair signed-rank test and Mann-Whitney
U test for nonparametric, respectively) were used to assess
differences between the groups. The Pearson correlation
coefficient (Spearman for nonparametric) was calculated
to assess the correlations between different variables. All
data are expressed as mean ± SD. P < 0.05 was considered
significant. The sample size calculation was measured using
G*Power software Version 3.1.9.4 for Macintosh (Heinrich-
Heine-Universität Düsseldorf, Düsseldorf, Germany). With
the effect size of 0.5, α of 0.05, and β of 80%, a minimal
sample size of 27 subjects was calculated to establish a
change. The graphs were created using GraphPad Prism
Version 7.0c for Macintosh (GraphPad Software, La Jolla,
CA, USA).
RESULTS
Clinical and Neuropathy Assessment
Baseline. Patients with diabetes and healthy controls
were comparable for age (54.08 ± 15.86 vs. 49.47 ± 13.25;
P = 0.2), sex (P = 0.6), ethnicity (P = 0.2), and BMI
(P = 0.1). The mean duration of follow-up in controls was
5.0 ± 1.75 years, and for patients with diabetes it was
3.6 ± 1.3 years (Table 1). High-density lipoprotein (HDL;
P = 0.8), systolic (P = 0.2) and diastolic (P = 0.8) BP were
comparable between patients with diabetes and controls.
HbA1c was higher and total cholesterol and low-density
lipoprotein (LDL; all P < 0.0001) and triglycerides (P = 0.04)
were lower in diabetic patients compared with controls.
NDS, VPT, and WPT were higher and CPT and PMNCV were
lower in patients with diabetes compared with controls (all
P = 0.001).
Controls Baseline Versus Follow-Up. There was a
reduction in total cholesterol (P = 0.05), but no change in
BMI (P = 0.8), HDL (P = 0.5), LDL (P = 0.1), triglycerides
(P = 0.7), or systolic and diastolic BP (both P = 0.9) between
baseline and follow-up. NDS (P = 0.1), VPT (P = 0.5), CPT
(P = 0.1), WPT (P = 0.4), and PMNCV (P = 0.3) did not
change between baseline and follow-up (Table 1).
Diabetic Patients Baseline Versus Follow-Up.
There was a significant reduction in total cholesterol
(P = 0.02) and LDL (P = 0.02), but no change in BMI
(P = 0.08), HbA1c (P = 0.2), HDL (P = 0.2), triglycerides
(P = 0.4), systolic (P = 0.9) or diastolic (P = 0.08) BP. There
was a significant increase in VPT (P = 0.02) (change per year
1.12 ± 2.75 V), but decrease in WPT (P = 0.01) (change per
year –0.33°C ± 2.19°C), with no change in NDS (P = 0.08),
CPT (P = 0.06), or PMNCV (P = 0.2) (Table 1) .
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TABLE 1. Demographics and Neuropathy Assessment in Healthy Controls and Patients with Diabetes at Baseline and Follow-Up
Controls Controls Patients Patient
Baseline Follow-Up P Value Baseline Follow-Up P Value
Age (y) 49.47 ± 13.25 NA 54.08 ± 15.86 NA
Sex (F/M) (7/12) (11/19)
Ethnicity (Asian/European) (4/15) (3/27)
Duration of diabetes (y) 0 ± 0 NA 23.95 ± 14.2 NA
Duration of follow-up (y) 5.0 ± 1.75 (1–8 y) 3.6 ± 1.3 (1–6 y)
HbA1c (%) 5.37 ± 0.42 5.28 ± 0.24 0.08 7.51 ± 1.37‡ 7.14 ± 1.07 0.2
BMI (kg/m2) 25.76 ± 3.66 27.26 ± 3.02 0.8 28.81 ± 6.69 28.34 ± 5.8 0.08
Cholesterol (mmol/mL) 4.98 ± 0.86 4.65 ± 0.83 0.05 3.95 ± 0.81‡ 3.73 ± 0.63 0.02
HDL (mmol/mL) 1.53 ± 0.31 1.61 ± 0.3 0.5 1.5 ± 0.5 1.47 ± 0.49 0.2
Triglycerides(mmol/mL) 1.58 ± 0.94 1.37 ± 0.51 0.7 1.17 ± 0.58* 1.32 ± 0.94 0.4
LDL (mmol/mL) 2.74 ± 0.76 2.55 ± 0.66 0.1 1.94 ± 0.57† 1.59 ± 0.49 0.02
Systolic BP (mm Hg) 120.21 ± 16.49 121 ± 16.56 0.9 126.2 ± 15.16 128.56 ± 17.32 0.9
Diastolic BP (mm Hg) 68.95 ± 10.64 68 ± 7.37 0.9 68.63 ± 7.85 65.88 ± 8.63 0.08
VPT (V) 6.83 ± 5.53 6.67 ± 4.21 0.5 12.9 ± 8.96† 13.78 ± 8.99 0.02
CPT foot (°C) 27.08 ± 4.33 22.53 ± 7.37 0.1 17.7 ± 10.59‡ 22.45 ± 9.23 0.06
WPT foot (°C) 39.27 ± 3.97 41.38 ± 5.28 0.4 43.56 ± 4.43† 40.78 ± 4.93 0.01
PMNCV (m/s) 48.22 ± 4.1 47.25 ± 4 0.3 42.4 ± 4.21‡ 42.16 ± 6.3 0.2
NDS (0–10) 0 0 0.1 3.38 ± 3.35† 2.61 ± 2.8 0.08
All data are presented as mean ± SD. NA, not available.
* P < 0.05 compared with controls baseline.
† P < 0.01 compared with controls baseline.
‡ P < 0.0001 compared with controls baseline.
TABLE 2. Corneal Nerve Parameters in Healthy Controls and Patients with Diabetes at Baseline and Follow-Up
Controls Baseline Controls Follow-Up P Value Patients Baseline Patients Follow-Up P Value
CNFD (no/mm2) 31.37 ± 5.31 31.02 ± 5.4 0.9 27.12 ± 8.2† 25.43 ± 7.11 0.2
CNBD (no/mm2) 87.53 ± 29.69 68.49 ± 24.95 0.02 57.72 ± 30.08† 44.04 ± 23.69 0.02
CNFL (mm/mm2) 26.07 ± 6.42 21.08 ± 4.52 0.01 21.77 ± 5.19* 15.65 ± 4.7 <0.0001
IWL (mm/mm2) 33.6 ± 10.11 29.79 ± 8.93 0.1 24.69 ± 8.67† 14.23 ± 6.13 <0.0001
ANFL (mm/mm2) 31.04 ± 6.54 26.11 ± 8.02 0.01 23.26 ± 5.53‡ 15.09 ± 4.48 <0.0001
All data are presented as mean ± SD.
* P < 0.05 compared with controls baseline.
† P < 0.01 compared with controls baseline.
‡ P < 0.0001 compared with controls baseline.
Corneal Confocal Microscopy
Baseline. CNFD (no/mm2) (27.12 ±
8.2 vs. 31.37 ± 5.31; P = 0.004), CNBD
(no/mm2) (57.72 ± 30.08 vs. 87.53 ± 29.69;
P = 0.002), CNFL (mm/mm2) (21.77 ± 5.19 vs. 26.07
± 6.42; P = 0.03), IWL (mm/mm2) (24.69 ± 8.67 vs. 33.6 ±
10.11; P = 0.003), and ANFL (mm/mm2) (23.26 ± 5.53 vs.
31.04 ± 6.54; P = 0.01) were significantly lower in patients
with diabetes compared with controls (Table 2, Fig. 1).
Controls Baseline Versus Follow-Up. There was a
significant reduction in CNBD (P = 0.02), CNFL (P = 0.01),
and ANFL (P = 0.01), but no change in CNFD (P = 0.9)
or IWL (P = 0.1) between baseline and follow-up visits
(Table 2, Fig. 2).
Diabetic Patients Baseline Versus Follow-Up.
There was a significant reduction in CNBD (P = 0.02), CNFL
(P < 0.0001), IWL (P < 0.0001), and ANFL (P < 0.0001), but
no change in CNFD (P = 0.2) between baseline and follow-
up visits (Table 2, Fig. 2).
Corneal Nerve Parameter Change per Year. To
measure the average rate of corneal nerve loss, we divided
the change between the baseline and follow-up visit by the
time between the baseline and follow-up visit. The change
per year in CNFL (mm/mm2) (2.08 ± 2.02 vs. 0.5 ± 3.35;
P = 0.02), ANFL (mm/mm2) (2.52 ± 1.51 vs. 0.67 ± 2.27;
P < 0.0001), and IWL (mm/mm2) (3.5 ± 2.91 vs. 0.68 ± 2.21;
P< 0.0001) was significantly higher in patients with diabetes
compared with healthy controls (Table 3). The intraclass
correlations showed good consistency between the changes
per year in CNFL and IWL in patients with diabetes (intra-
class correlation coefficient, 0.78; 95% confidence interval,
0.56–0.88; P < 0.0001).
DISCUSSION
There is currently no consensus as to which corneal nerve
parameter has optimal sensitivity and specificity for the
diagnosis and assessment of progression or benefit after
therapeutic intervention in diabetic neuropathy.20,21 Earlier
studies suggested that CNFD20,21 may be optimal in the diag-
nosis of DPN, whereas others have shown that CNFL is a
more reliable parameter for both diagnosis and prediction
of the development of diabetic neuropathy.22–24 However,
longitudinal studies ideally require quantification of the
same corneal nerves over time, and as there is significant
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FIGURE 1. CCM images of the central cornea (first row) and IW (second row) in a healthy control at baseline (A, E) and follow-up (B, F),
and an age-matched patient with diabetes at baseline (C, G) and follow-up (D, H). Scale bar: 50 pixels.
FIGURE 2. (A) CNFL and (B) IWL in patients with diabetes at baseline and follow-up (each dot represents a single patient).
heterogeneity in the central corneal nerve network, it can
be difficult to capture the same area.25
Quantification of corneal nerve morphology at the IW
has several distinct advantages as it assesses an anatomically
more distal part of the sub-basal plexus compared with the
central nerves,6 and is therefore more likely to be affected
by a dying back neuropathy and it is also a unique landmark
for longitudinal studies. At baseline, all corneal nerve param-
eters in the central and IW region were reduced in patients
with diabetes compared with healthy controls, in agreement
with previous studies.10–12,19 Furthermore, in patients with
diabetes a change in more distal nerve fibers as captured by
CNBD, CNFL, IWL, and ANFL showed a significant reduction
at follow-up, whereas CNFD, a more proximal part of the
TABLE 3. Corneal Nerve Parameter Changes per Year in Healthy Controls and Patients with Diabetes
Controls Change Per Year Patients Change Per Year P Value
CNFD (no/mm2) 0.07 ± 0.85 0.28 ± 2.2 0.1
CNBD (no/mm2) 3.08 ± 9.21 4.19 ± 7.95 0.9
CNFL (mm/mm2) 0.5 ± 3.35 2.08 ± 2.02 0.02
ANFL (mm/mm2) 0.67 ± 2.27 2.52 ± 1.51 <0.0001
IWL (mm/mm2) 0.68 ± 2.21 3.5 ± 2.91 <0.0001
This table shows the average reduction per year. All data are presented as mean ± SD.
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corneal nerve plexus, did not change, indicating that these
more distal nerve parameters are more capable of capturing
change in CCM over time. Pritchard et al.8 have also previ-
ously demonstrated a reduction in CNFL and CNBD, with
no change in CNFD in patients with type 1 diabetes. We
also demonstrated a significant reduction in CNFL in healthy
controls, consistent with the study of Dehghani et al.15 who
reported a slight reduction in CNFL over 36 months. More
recently, we have shown that corneal nerve loss has the
greatest predictive value for the development of DPN.26
As expected, we also show that the rate of annual decline
in CNFL, IWL, and ANFL was significantly higher in patients
with diabetes compared with controls.27 Our previous study
also showed a two- to three-fold greater reduction in IWL
compared with CNFL in patients with DPN compared with
healthy controls.11
All other accepted measures of diabetic neuropathy
differed from healthy controls. However, over time whereas
the controls showed no change, diabetic patients showed a
small but significant worsening in VPT with no change in
nerve conduction, whereas NDS and CPT showed trends for
improvement and WPT improved significantly. This suggests
that these measures have significant limitations when assess-
ing longitudinal change, especially in small cohorts of
patients with diabetes, especially in early phase 2 clinical
trials.
To our knowledge, this is the first longitudinal study
comparing corneal nerve loss in the central and IW
regions. Our study shows that corneal nerve loss at base-
line and over time is greater in the IW compared with
the central cornea in controls and patients with diabetes.
The reduction in CNFL in control subjects in the present
study was greater than that reported by Sharma et al.,28
but our controls were older, and we assessed CNFL
manually.
Cardiovascular risk factors, including glycemic control,
BP, and lipids, have been associated with the develop-
ment of diabetic neuropathy.29 A large body of exper-
imental and clinical data suggests an important link
between dyslipidemia and diabetic neuropathy.30 A reduc-
tion in corneal nerves has been associated with increas-
ing age, HbA1c, and a lower HDL.14 We have also recently
shown that an improvement in corneal nerve morphology
after pancreas and kidney transplantation was associated
with an improvement in HbA1c and triglycerides.31 The
ADDITION-Denmark study showed that LDL and choles-
terol are risk factors for the development of DPN.32 In
the present study, we showed a significant improvement
in total cholesterol and LDL attributed to statin treat-
ment, but there was a reduction in all CCM parameters at
follow-up.
CONCLUSIONS
Our study shows greater corneal nerve loss at the IW at
follow-up compared with baseline. Furthermore, the mini-
mal change or indeed improvement in accepted measures
of diabetic neuropathy questions the utility of these tests in
longitudinal and therapeutic studies of diabetic neuropathy.
Acknowledgments
Supported by the Manchester Biomedical Research Centre
and the Greater Manchester Comprehensive Local Research
Network. Also supported by the European Union Seventh
Framework Programme FP7/2007-2013 (n°602273), National
Institutes of Health (R01DK077903-0101; Bethesda, MD, USA),
and Juvenile Diabetes Research Foundation International (27-
2008-362). The authors alone are responsible for the content
and writing of the article.
Author contributions: MF researched data, performed statisti-
cal analysis, and wrote the manuscript; AK researched data,
performed statistical analysis, and wrote the manuscript; IP
researched data; SA researched data; SD researched data; AM
researched data; AJMB reviewed and revised the manuscript; NE
reviewed and revised the manuscript; CGF reviewed and revised
the manuscript; GL reviewed and revised the manuscript; HS
reviewed and revised the manuscript; RAM designed the study
and reviewed and revised the manuscript. RAM is the guaran-
tor of this work and, as such, had full access of the data of the
study and takes responsibility of the integrity of the data and
the accuracy of the data analyses.
Disclosure: M. Ferdousi, None; A. Kalteniece, None; I.
Petropoulos, None; S. Azmi, None; S. Dhage, None; A.
Marshall, None; A.J.M. Boulton, None; N. Efron, None; C.G.
Faber, None; G. Lauria, None; H. Soran, None; R.A. Malik,
None
References
1. Oliveira Soto L. Morphology of corneal nerves using confo-
cal microscopy. Cornea. 2001;20:374–3784.
2. Petropoulos IN, Alam U, Fadavi H, et al. Corneal nerve
loss detected with corneal confocal microscopy is symmet-
rical and related to the severity of diabetic polyneuropathy.
Diabetes Care. 2013;36:3646–3651.
3. Petropoulos IN, Green P, Chan AW, et al. Corneal confo-
cal microscopy detects neuropathy in patients with type 1
diabetes without retinopathy or microalbuminuria. PLoS
One. 2015;10:e0123517.
4. Perkins BA, Lovblom LE, Bril V, et al. Corneal confo-
cal microscopy for identification of diabetic sensorimotor
polyneuropathy: a pooled multinational consortium study.
Diabetologia. 2018;61:1856–1861.
5. Patel DV, McGhee CN. Mapping of the normal human
corneal sub-basal nerve plexus by in vivo laser scan-
ning confocal microscopy. Invest Ophthalmol Vis Sci.
2005;46:4485–4488.
6. Muller LJ, Marfurt CF, Kruse F, Tervo TM. Corneal nerves:
structure, contents and function. Exp Eye Res. 2003;76:521–
542.
7. Malik RA, Kallinikos P, Abbott CA, et al. Corneal confocal
microscopy: a non-invasive surrogate of nerve fibre damage
and repair in diabetic patients. Diabetologia. 2003;46:683–
688.
8. Pritchard N, Edwards K, Dehghani C, et al. Longitudinal
assessment of neuropathy in type 1 diabetes using novel
ophthalmic markers (LANDMark): study design and base-
line characteristics. Diabetes Res Clin Pract. 2014;104:248–
256.
9. Davidson EP, Coppey LJ, Kardon RH, Yorek MA. Differ-
ences and similarities in development of corneal nerve
damage and peripheral neuropathy and in diet-induced
obesity and type 2 diabetic rats. Invest Ophthalmol Vis Sci.
2014;55:1222–1230.
10. Petropoulos IN, Ferdousi M, Marshall A, et al. The inferior
whorl for detecting diabetic peripheral neuropathy using
corneal confocal microscopy. Invest Ophthalmol Vis Sci.
2015;56:2498–2504.
11. Kalteniece A, Ferdousi M, Petropoulos I, et al. Greater
corneal nerve loss at the inferior whorl is related to the pres-
Downloaded from iovs.arvojournals.org on 04/09/2020
Corneal nerve Loss in Diabetic Neuropathy IOVS | March 2020 | Vol. 61 | No. 3 | Article 48 | 6
ence of diabetic neuropathy and painful diabetic neuropa-
thy. Sci Rep. 2018;8:3283.
12. Utsunomiya T, Nagaoka T, Hanada K, et al. Imaging of the
corneal subbasal whorl-like nerve plexus: more accurate
depiction of the extent of corneal nerve damage in patients
with diabetes. Invest Ophthalmol Vis Sci. 2015;56:5417–
5423.
13. Pritchard N, Dehghani C, Edwards K, et al. Utility of assess-
ing nerve morphology in central cornea versus whorl area
for diagnosing diabetic peripheral neuropathy. Cornea.
2015;34:756–761.
14. Dehghani C, Pritchard N, Edwards K, Russell AW, Malik
RA, Efron N. Risk factors associated with corneal nerve
alteration in type 1 diabetes in the absence of neuropathy:
a longitudinal in vivo corneal confocal microscopy study.
Cornea. 2016;35:847–852.
15. Dehghani C, Pritchard N, Edwards K, et al. Morphometric
stability of the corneal subbasal nerve plexus in healthy
individuals: a 3-year longitudinal study using corneal confo-
cal microscopy. Invest Ophthalmol Vis Sci. 2014;55:3195–
3199.
16. Dehghani C, Pritchard N, Edwards K, et al. Natural history
of corneal nerve morphology in mild neuropathy associated
with type 1 diabetes: development of a potential measure of
diabetic peripheral neuropathy. Invest Ophthalmol Vis Sci.
2014;55:7982–7990.
17. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen
PH. A multicentre study of the prevalence of diabetic
peripheral neuropathy in the United Kingdom hospital
clinic population. Diabetologia. 1993;36:150–154.
18. Tavakoli M, Malik RA. Corneal confocal microscopy: a novel
non-invasive technique to quantify small fibre pathology in
peripheral neuropathies. J Vis Exp. 2011;47:2194.
19. Kalteniece A, Ferdousi M, Adam S, et al. Corneal confo-
cal microscopy is a rapid reproducible ophthalmic tech-
nique for quantifying corneal nerve abnormalities. PLoS
One. 2017;12:e0183040.
20. Ziegler D, Papanas N, Zhivov A, et al. Early detection of
nerve fiber loss by corneal confocal microscopy and skin
biopsy in recently diagnosed type 2 diabetes. Diabetes.
2014;63:2454–2463.
21. Tavakoli M, Quattrini C, Abbott C, et al. Corneal confo-
cal microscopy: a novel noninvasive test to diagnose and
stratify the severity of human diabetic neuropathy. Diabetes
Care. 2010;33:1792–1797.
22. Hertz P, Bril V, Orszag A, et al. Reproducibility of in vivo
corneal confocal microscopy as a novel screening test for
early diabetic sensorimotor polyneuropathy. Diabet Med.
2011;28:1253–1260.
23. Ahmed A, Bril V, Orszag A, et al. Detection of diabetic senso-
rimotor polyneuropathy by corneal confocal microscopy in
type 1 diabetes: a concurrent validity study. Diabetes Care.
2012;35:821–828.
24. Lovblom LE, Halpern EM, Wu T, et al. In vivo
corneal confocal microscopy and prediction of future-
incident neuropathy in type 1 diabetes: a prelimi-
nary longitudinal analysis. Can J Diabetes. 2015;39:390–
397.
25. Lv Y, Zhao SZ. What is the best strategy on detection
of cornea neuropathy in people with diabetes? Recent
advances in potential measurements. Diabetes Res Clin
Pract. 2018;142:203–212.
26. Edwards K, Pritchard N, Dehghani C, et al. Corneal
confocal microscopy best identifies the development
and progression of neuropathy in patients with type
1 diabetes. J Diabetes Complications. 2017;31:1325–
1327.
27. Tesfaye S, et al. Diabetic neuropathies: update on defini-
tions, diagnostic criteria, estimation of severity, and treat-
ments. Diabetes Care. 2010;33:2285–2293.
28. Sharma S, Tobin V, Vas PRJ, Malik RA, Rayman G. The influ-
ence of age, anthropometric and metabolic variables on
LDIFLARE and corneal confocal microscopy in healthy indi-
viduals. PLoS One. 2018;13:e0193452.
29. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors
and diabetic neuropathy. N Engl J Med. 2005;352:341–
350.
30. Eid S, Sas KM, Abcouwer SF, et al. New insights
into the mechanisms of diabetic complications: role of
lipids and lipid metabolism. Diabetologia. 2019;62:1539–
1549.
31. Azmi S, Jeziorska M, Ferdousi M, et al. Early nerve fibre
regeneration in individuals with type 1 diabetes after simul-
taneous pancreas and kidney transplantation. Diabetologia.
2019;62:1478–1487.
32. Andersen ST, Grosen K, Tankisi H, et al. Corneal
confocal microscopy as a tool for detecting diabetic
polyneuropathy in a cohort with screen-detected type 2
diabetes: ADDITION-Denmark. J Diabetes Complications.
2018;32:1153–1159.
Downloaded from iovs.arvojournals.org on 04/09/2020
